JHL Biotech's Final Trading Day on Taipei Exchange
HSINCHU and WUHAN, China, Feb. 12, 2018 /PRNewswire/ -- JHL Biotech
JHL Biotech Welcomes New Chief Medical Officer, Rong Chen
HSINCHU and WUHAN, China, Jan. 2, 2018 /PRNewswire/ -- JHL Biotech
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis
HSINCHU, Taiwan and WUHAN, mainland China, Dec. 21, 2017 /PRNewswire/ -- JHL
Biotech
Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China
SHANGHAI, Dec. 5, 2016 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities inWuhan and Taiwan, announced today a strategic alliance to collaborate on the develo...
JHL Biotech Announces Mechanical Completion of its Wuhan Biopharmaceutical Manufacturing Facility
WUHAN, China and AMERSHAM, England, Feb. 25, 2016 /PRNewswire/ -- JHL Biotech
(TPEx: 6540) and GE Healthcare's Life Sciences business (NYSE: GE) are proud to
announce mechanical completion of JHL Biotech's JHL-1 biopharmaceutical
manufacturing facility in the Biolake area ofWuhan, China.
JHL Biotech Receives Approval From European Authorities to Begin Biosimilar Clinical Trial
HSINCHU, , Feb. 15, 2016 /PRNewswire/ -- JHL Biotech, Inc. (Stock Code: 6540.TWO) announced it has received authorization from theUnited Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to begin clinical trial for JHL1101, a rituximab biosimilar developed and manufactured ...
